A number of firms have modified their ratings and price targets on shares of MacroGenics (NASDAQ: MGNX) recently:

  • 8/12/2017 – MacroGenics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/7/2017 – MacroGenics had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an “equal weight” rating on the stock.
  • 8/4/2017 – MacroGenics had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 8/3/2017 – MacroGenics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/3/2017 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 7/31/2017 – MacroGenics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – MacroGenics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $19.00 price target on the stock. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 7/11/2017 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

Shares of MacroGenics, Inc. (NASDAQ MGNX) opened at 16.62 on Wednesday. MacroGenics, Inc. has a 12-month low of $14.36 and a 12-month high of $32.68. The stock has a 50 day moving average of $17.24 and a 200-day moving average of $18.69. The company’s market capitalization is $611.58 million.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.09. The business had revenue of $1.70 million during the quarter, compared to analyst estimates of $15.82 million. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. MacroGenics’s quarterly revenue was down 97.9% on a year-over-year basis. During the same quarter last year, the company earned $1.12 earnings per share. Equities research analysts forecast that MacroGenics, Inc. will post ($4.36) EPS for the current year.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the sale, the senior vice president now directly owns 35,000 shares in the company, valued at $700,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.30% of the stock is owned by corporate insiders.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.